
Surgery Partners (SGRY) Stock Forecast & Price Target
Surgery Partners (SGRY) Analyst Ratings
Bulls say
Surgery Partners Inc. is experiencing favorable payor mix dynamics, with private insurance revenue share increasing by 100 basis points to 53.5%, while government payor mix decreased, indicating a healthier revenue structure. The company reported an impressive organic revenue growth of 8.0% year-over-year in 2024, driven by a 5.1% growth in same-facility day-adjusted case volume and a 4.0% increase in revenue per case, which are expected to continue benefiting from strategic investments in higher acuity specialties. Additionally, adjusted EBITDA margins improved, with a rise from 16.0% to 16.3%, and 2025 guidance anticipates further margin expansion to 16.4%-16.8%, supported by effective revenue-cycle management and operational efficiencies.
Bears say
Surgery Partners Inc. has experienced a fourth-quarter adjusted EBITDA margin of 18.9%, which is below both the market expectations of 19.8% and the 19.4% recorded in the same quarter of the previous year, despite a slight increase in revenue. The company’s stock has seen a significant decline of 31% since the last earnings report, attributed to disappointed investor sentiment stemming from higher transaction-related costs and negative revisions to free cash flow and earnings per share. Additionally, upcoming healthcare policy uncertainties and projected revenue and EBITDA headwinds for 2025 further contribute to a negative outlook for the company’s financial performance.
This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.
Surgery Partners (SGRY) Analyst Forecast & Price Prediction
Start investing in Surgery Partners (SGRY)
Order type
Buy in
Order amount
Est. shares
0 shares